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ABSTRACT
This report briefly discusses a case of retroperitoneal Castleman’s disease in a 52 year
old post-menopausal woman with renal cell carcinoma.
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INTRODUCTION
Castleman’s disease is a rare, benign,
lymphoproliferative disorder first described in 1954
that affects less than 200,000 people in the United
States.1 While most cases involve the thorax, 15%
of cases affect the abdomen or pelvis.2 Castleman’s
disease is subdivided into two histopathological
subtypes: hyaline-vascular variant or plasma cell
variant.1 The hyaline-vascular variant is associated
with abnormal lymphoid follicular hyperplasia and
increased interfollicular vascularity while the plasma
cell variant is distinguished by sheets of mature
plasma cells on histology.3
Castleman’s disease is further divided clinically into
unicentric or multicentric disease. Unicentric, or
localized disease, is typically asymptomatic and has
well circumscribed lesions with moderate to intense
enhancement on imaging. Multicentric disease
typically presents with systemic systems such as
fever, night sweats, peripheral lymphadenopathy, or
hepatosplenomegaly, and is often associated with
human immunodeficiency virus (HIV) or human
herpes virus-8 (HHV-8) infection, and is harder to
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distinguish from lymphoproliferative disorders.1,3
In localized disease, 85- 90% of cases are hyalinevascular variant.1 Most are found incidentally on
imaging as patients are asymptomatic or have few
symptoms with vague complaints.3 Radiological
appearance is often nonspecific, so diagnosis must
be made via biopsy or surgical resection.4 We report
a case of retroperitoneal unicentric Castleman’s
disease found incidentally in a patient with renal cell
carcinoma.
CASE REPORT
A 52 year old postmenopausal female presented
to her primary care physician complaining of
generalized abdominal tenderness and heavy
vaginal bleeding for several weeks. The patient was
given Provera 5 mg daily to control the bleeding. A
computed tomography (CT) scan without contrast
at this time showed a partially calcified right lower
quadrant retroperitoneal mass of at least 5.2 cm
concerning for malignancy, an enlarged uterus
with possible leiomyoma, and a mass in the lower
pole of the left kidney. CT-guided biopsy of the
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retroperitoneal mass was non-diagnostic. Labs at this
time showed normocytic anemia with a hemoglobin
of 7.8 g/dL. A referral to urologic oncology and
gynecologic oncology was made.
A retroperitoneal ultrasound showed a
heterogeneous solid mass in the inferior left kidney.
An endometrial biopsy showed complex endometrial
hyperplasia with atypia. A repeat CT with and
without contrast showed a solid enhancing mass
of the inferior pole of the left kidney (5.1 x 4.4 x
4.3 cm) concerning for renal cell carcinoma and a
lipomatous mass with irregular central calcification
in the retroperitoneum of the right lower quadrant
(soft tissue mass measuring 5.4 cm) unchanged
from prior CT scan concerning for liposarcoma.
Positron emission tomography (PET)/ CT imaging
prior to surgery showed hypermetabolic activity
in the retroperitoneal mass, mass of left kidney,
thyroid, and the uterus. The centrally calcified soft

tissue component of the retroperitoneal mass was
hypermetabolic with peak standardized uptake
value (SUV) of 5.1 concerning for malignant sarcoma.
Decision was made to undergo robotic-assisted
total laparoscopic hysterectomy, bilateral salpingooophorectomy, excision of retroperitoneal mass,
and partial nephrectomy of left kidney. During
surgery, partial left nephrectomy was converted to
left radical nephrectomy. The surgery was otherwise
uncomplicated. Specimens obtained included left
kidney and ureter, miscellaneous renal fragments, 10
cm retroperitoneal mass, uterus, bilateral fallopian
tubes, bilateral ovaries, cervix, and pelvic washings.
Pathology included: left kidney mass showing stage
1b clear cell renal cell carcinoma limited to the
kidney, uterus showing endometrial hyperplasia
with atypia with multiple leiomyomas, and the
retroperitoneal mass was diagnosed as hyaline
vascular variant Castleman disease. Patient’s postoperative period was uncomplicated.
DISCUSSION
While the etiology of Castleman’s disease is
unknown, development of the disease is thought
to be attributed to an autoimmune process,
immunodeficiency, chronic low-grade inflammation,
or lymphoid hamartomatous hyperplasia.2

IMAGE 1. Gross picture of retroperitoneal mass
with hyaline Castleman disease.
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Our patient diagnosed with stage 1b renal cell
carcinoma is in a state of chronic inflammation,
which we hypothesize may have contributed to
her disease process. Our patient presented with
vague symptoms which is consistent with localized,
unicentric Castleman’s disease with hyaline-vascular
variant.3 However, due to our patient’s unique
situation of presenting with both Castleman’s
disease and renal cell carcinoma, it is unclear which
etiology was causing her presenting symptoms.
Our patient’s repeat CT scan initially was concerning
for a liposarcoma and further imaging with PET/
CT scan was concerning for sarcoma. Common
differential diagnoses for Castleman’s disease
should include retroperitoneal sarcoma, lymphoma,
desmoid tumor, carcinoid, or adenopathy.1,2
Therefore, sarcoma is a common misdiagnosis
for Castleman’s disease and should be part of
a differential diagnosis with retroperitoneal
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IMAGE 2. Microscopic picture of this case showing a) Depleted germinal center and expanded mantle
zones, b) Expanded interfollicular area with hyalinized vessels, c) Regressed follicles with expanded
interfollicular area, d) Depleted germinal center with penetrating vessels (“lollipop” appearance)

TABLE 1. Comparison of Unicentric/ Localized and Multicentric Castleman’s disease3.
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masses. In hyaline-vascular variant disease, 10% of
masses are partially calcified, which is consistent
with our patient who had centrally calcified soft
tissue mass on CT scan.2 While smaller masses
may be homogeneous, larger masses are often
heterogeneous due to central necrosis.3 PET
imaging of Castleman’s disease often demonstrates
an SUV of fluorodeoxyglucose (FDG) in a range
lower than seen in patients with lymphoma, which
may be able to help differentiate between benign
Castleman’s disease and malignant lymphoma.4
Ngeow et al. states that FDG uptake greater than
10 SUV is predictive of an aggressive B-cell lineage
or suggestive of more aggressive histological
components5. Our patient had an SUV of 5.1, which is
lower than this predictive value.
Our patient was diagnosed via tissue biopsy after
full surgical resection of the peritoneal mass.
Due to the locally invasive nature of the tumor,
patient’s symptoms respond well to surgical
resection.1 Complete surgical resection of the mass
is considered curative, and recurrence has only been
described after incomplete surgical resections.6
Therefore, our patient was treated according to the
standard of care. Five year survival rate is nearly
100% in full surgical resection.6 In multicentric
disease, systemic chemotherapy is required and
mean survival is fourteen to thirty months.1 Our
patient will have repeat imaging with a CT of chest,
abdomen, and pelvis three months after surgery as
well as continual follow up with a medical oncologist
regarding her renal cell carcinoma.
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